Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1966 2
1967 1
1968 5
1969 3
1970 6
1971 5
1972 4
1973 5
1974 4
1975 14
1976 13
1977 6
1978 9
1979 11
1980 19
1981 11
1982 8
1983 10
1984 12
1985 9
1986 16
1987 5
1988 6
1989 9
1990 8
1991 8
1992 9
1993 13
1994 10
1995 7
1996 12
1997 13
1998 28
1999 14
2000 9
2001 9
2002 14
2003 16
2004 18
2005 8
2006 9
2007 13
2008 23
2009 17
2010 27
2011 26
2012 26
2013 32
2014 41
2015 27
2016 38
2017 26
2018 25
2019 20
2020 27
2021 10
2022 9
2023 12
2024 8

Search Results

741 results

Results by year

Filters applied: . Clear all
Page 1
Crippling down factor IX for therapeutic gain.
Strijbis VJF, Vatandoost J, Bos MHA. Strijbis VJF, et al. J Thromb Haemost. 2023 Dec;21(12):3287-3291. doi: 10.1016/j.jtha.2023.08.030. Epub 2023 Sep 6. J Thromb Haemost. 2023. PMID: 37678545 Review. No abstract available.
Recombinant factor IX for clinical and research use.
Monahan PE, Di Paola J. Monahan PE, et al. Semin Thromb Hemost. 2010 Jul;36(5):498-509. doi: 10.1055/s-0030-1255444. Epub 2010 Jul 14. Semin Thromb Hemost. 2010. PMID: 20632248 Review.
Factor IX concentrates for clinical use.
Thompson AR. Thompson AR. Semin Thromb Hemost. 1993;19(1):25-36. doi: 10.1055/s-2007-994003. Semin Thromb Hemost. 1993. PMID: 8456321 Review. No abstract available.
Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial.
Bouzat P, Charbit J, Abback PS, Huet-Garrigue D, Delhaye N, Leone M, Marcotte G, David JS, Levrat A, Asehnoune K, Pottecher J, Duranteau J, Courvalin E, Adolle A, Sourd D, Bosson JL, Riou B, Gauss T, Payen JF; PROCOAG Study Group. Bouzat P, et al. JAMA. 2023 Apr 25;329(16):1367-1375. doi: 10.1001/jama.2023.4080. JAMA. 2023. PMID: 36942533 Free PMC article. Clinical Trial.
A study of reported factor IX use around the world.
Stonebraker JS, Bolton-Maggs PH, Brooker M, Farrugia A, Srivastava A. Stonebraker JS, et al. Haemophilia. 2011 May;17(3):446-55. doi: 10.1111/j.1365-2516.2010.02461.x. Epub 2011 Feb 7. Haemophilia. 2011. PMID: 21299742
Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.
Windyga J, Timofeeva M, Stasyshyn O, Mamonov V, Lamas Castellanos JL, Lissitchkov T, Chojnowski K, Chapman M, Pavlova BG, Tangada S. Windyga J, et al. Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620946839. doi: 10.1177/1076029620946839. Clin Appl Thromb Hemost. 2020. PMID: 32816519 Free PMC article. Clinical Trial.
741 results